Phase 3 RCT in 325 men with high-risk localised prostate cancer and undetectable PSA after prostatectomy: 24 months of leuprorelin did not improve 10-year metastasis-free survival vs observation (HR 0.63, p=0.204) and raised adverse events.
RCTn = 325
Rozet et al. Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer